



HHS Public Access

Author manuscript

Mol Neurobiol. Author manuscript; available in PMC 2020 July 01.

Published in final edited form as:

Mol Neurobiol. 2019 July ; 56(7): 4880–4893. doi:10.1007/s12035-018-1403-3.

Ferroptosis and its Role in Diverse Brain Diseases

Abigail Weiland¹, Yamei Wang², Weihua Wu², Xi Lan¹, Xiaoning Han¹, Qian Li^{2,3}, and Jian Wang¹

¹Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

²Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China.

³Advanced Innovation Center for Human Brain Protection, Beijing 100069, China.

Abstract

Ferroptosis is a recently identified, iron-regulated, non-apoptotic form of cell death. It is characterized by cellular accumulation of lipid reactive oxygen species that ultimately leads to oxidative stress and cell death. Although first identified in cancer cells, ferroptosis has been shown to have significant implications in several neurologic diseases, such as ischemic and hemorrhagic stroke, Alzheimer's disease, and Parkinson's disease. This review summarizes current research on ferroptosis, its underlying mechanisms, and its role in the progression of different neurologic diseases. Understanding the role of ferroptosis could provide valuable information regarding treatment and prevention of these devastating diseases.

Keywords

Ferroptosis; Brain disease; Stroke; Cancer

Introduction

Ferroptosis, first described by Dixon *et al.* in 2012, is a form of cell death characterized by accumulation of intracellular iron [1]. It is defined by depletion of plasma membrane unsaturated fatty acids and accumulation of iron-induced lipid reactive oxygen species (ROS) [2]. The over-accumulation of lipid ROS leads to an oxidative stress response in cells that causes lethal damage to proteins, nucleic acids, and lipids [3] and eventually to cell death. Thus, ferroptosis requires the coincident depletion of glutathione (GSH) or inactivation of glutathione-dependent antioxidant enzyme glutathione peroxidase 4 (GPX4) and the incorporation of oxidizable polyunsaturated fatty acids into phospholipids [4].

Address correspondence to: Qian Li, MD, PhD (Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China. qianli@ccmu.edu.cn.) or Jian Wang, MD, PhD (Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, 720 Rutland Ave, Ross Bldg 370B, Baltimore, MD 21205. Phone: 443-287-5490; jwang79@jhmi.edu).

Author contributions: AW, YW, WW, QL, and JW wrote the manuscript; AW, YW, XH, XL, QL, and JW revised the manuscript.

Conflict of interest statement: The authors have declared that no conflict of interest exists.

Ferroptosis differs from apoptosis, necrosis, and autophagy morphologically, biochemically, and genetically [1]. Under electron microscopy, ferroptotic cells exhibit shrunken mitochondria, whereas mitochondria are usually swollen in other forms of cell death [1]. Initially, Dixon *et al.* identified a distinct set of genes that regulate the ferroptotic mechanism, including ribosomal protein L8 (*RPL8*), iron response element binding protein 2 (*IREB2*), and ATP synthase F₀ complex subunit C3 (*ATP5G3*) [1]. Later studies showed that numerous genes/proteins participate in this unique cell death process, including cyclooxygenase-2 (*PTGS2*) [5], p53 [6], nuclear factor E2-related factor 2 (Nrf2) [7], PEBP1 [8], and more. In addition to those key regulators, ferroptosis can be induced by excessive glutamate, intracellular iron accumulation, or treatment with small molecules - for example, erastin, RSL3, and others listed in Table 1. The first ferroptosis-inducing compounds, erastin (which inhibits system x_c⁻, the glutamate/cystine antiporter) and Ras selective lethal 3 (RSL3, which directly inhibits GPX4), were discovered several years before identification of the ferroptosis concept [9,10]. Stockwell's group was surprised to find that cells treated with those compounds were neither apoptotic nor necroptotic [1,9–11], and that cell death could be inhibited by lipophilic antioxidants (α-tocopherol, butylated hydroxytoluene, and β-carotene), indicating that lipoxygenase activity and lipophilic ROS were involved in this cell death process [12–14].

Known inducers of ferroptosis can be divided into several categories: system x_c⁻ inhibitors (glutamate, erastin, sulfasalazine, and sorafenib), GSH depletion compounds (buthioninesulfoximine and acetaminophen), and GPX4 direct inhibitors (RSL3 and FIN56) [1,14,15]. Additionally, several molecules have been identified as inhibitors of ferroptosis, including ferrostatin-1 (Fer-1, which inhibits lipid ROS) [1], deferoxamine (DFO, which chelates iron) [1], zileuton (which inhibits 5-lipoxygenase) [16], and recently identified FINO₂ (which oxidizes iron) [17], depending on the mechanism of ferroptosis. In this review, we focus on ferroptosis in different brain diseases and summarize the primary inducers, regulators, and inhibitors of ferroptosis-associated brain disorders, as shown in Table 1.

Ferroptosis has been identified in various cancer cells, including breast [18], lung [1], lymphoma [19], kidney [20], and brain [21]. Strikingly, the inducers of ferroptosis have been shown to target and kill cancerous cells [22]. In 2015, Jiang *et al.* reported that ferroptosis also contributes to embryo development and that p53 plays a vital role in ferroptosis regulation [6]. More importantly, research in organotypic hippocampal slice cultures has shown that ferroptosis also contributes to neuronal death [1]. Indeed, we and others have shown a connection between ferroptosis and neurodegeneration in experimental intracerebral hemorrhage [23,24], Parkinson's disease [25], and periventricular leukomalacia [26]. In this article, we will systematically review the role of ferroptosis in different brain diseases, discuss our current understanding of the underlying mechanism, and describe the possible therapeutic strategies (Figures 1 and 2).

Ferroptosis in stroke

Stroke ranks number 5 among all causes of death, behind diseases of the heart, cancer, chronic lower respiratory disease, and unintentional injuries/accidents [27]. Each year,

approximately 795,000 people experience a new or recurrent stroke, 87% of which are ischemic strokes [27]. An ischemic stroke occurs when the blood supply to certain parts of the brain is restricted secondary to occlusion of the internal carotid, middle cerebral, or vertebral/basilar arteries [28]. The resulting depletion of oxygen and nutrients may cause cells to activate the ischemic cascade, which results in oxidative stress, mitochondrial impairment, and, ultimately, death [29]. Before ferroptosis was identified, it was already known that iron accumulation exaggerates neuronal damage during reperfusion both clinically and in animal models of ischemic stroke [30–36]. It had been shown that iron chelation reduces reperfusion damage in animals after an ischemic event [37–40]. In 2013, Speer *et al.* hypothesized that ferroptosis might contribute to neuronal death induced by cerebral ischemia and that hypoxia-inducible factor (HIF) prolyl hydroxylases might serve as a target for the beneficial effects of metal chelators [41]. They further postulated that the beneficial effects of iron chelators in preventing ferroptosis were due to inhibition of 2-oxoglutarate, oxygen-dependent dioxygenases, and the HIF prolyl hydroxylases, but not to direct inhibition of Fenton chemistry or ROS formation [41]. Then, in 2017, a study showed that ferroptosis inhibition protected mice against ischemia-reperfusion injury in a middle cerebral artery occlusion (MCAO) model, indicating that ferroptosis contributes to neuronal death after ischemic stroke. Interestingly, the authors found that tau knockout mice were protected from ferroptotic cell death after ischemia-reperfusion injury and introduced the tau–iron interaction as a pleiotropic modulator of ferroptosis and ischemic stroke outcome [42].

Intracerebral hemorrhage (ICH) accounts for 10–30% of all stroke cases and is associated with higher rates of mortality and morbidity than is ischemic stroke [27,43]. Until recently, apoptosis, necrosis, and autophagy were thought to be the only contributors to neuronal death after ICH [44–49]. However, solid data have shown the presence of neuronal ferroptosis after ICH *in vitro* and *in vivo* [23,50,51]. In 2014, we found that (–)-epicatechin, a brain-permeable flavanol, reduced early brain injury after ICH, in part by decreasing brain iron deposition and ferroptosis-related gene expression [24]. In 2017, Zille *et al.* found that a number of ferroptosis inhibitors, including Fer-1, DFO, N-acetylcysteine (which inhibits ROS and reactive lipid species), and Trolox (a vitamin E analog that targets reactive lipid species), were able to rescue mouse primary cortical neurons from hemin- and hemoglobin-induced death *in vitro* [50]. Additionally, they found that elevated phospho-ERK1/2 levels were associated with enhanced neuronal ferroptosis and that U0126, an MEK inhibitor, inhibited this cell death mechanism [50]. Notably, in erastin- or amino acid starvation-induced ferroptosis in cancer cells, the more selective and potent MEK inhibitor PD0325901 failed to block cell death. The authors claimed that U0126 had off-target effects and that the MEK-ERK1/2 signaling pathway was not involved in the ferroptotic mechanism [52]. Interestingly, Zille *et al.* found that necroptosis inhibitor necrostatin-1 also reduced hemin-induced cell death and that the treated cells exhibited a necrotic phenotype with loss of plasma membrane integrity and disintegration of organelles *in vitro*, indicating that ferroptosis may be an early stage of necrosis [50]. At the same time, we found that Fer-1 prevented hemoglobin-induced neuronal death and reduced GPX4 activity deficiency in brain slice cultures, and it rescued ferroptotic neurons and reduced cyclooxygenase-2 (Cox-2) expression in collagenase- and blood injection-induced ICH mouse models [23]. In

addition, using transmission electron microscopy, we showed that ferroptosis co-exists with necrosis and autophagy *in vivo* and that using a combination of inhibitors to target these different forms of cell death rescued neurons from hemoglobin-induced toxicity better than any inhibitor alone [23,51]. Recently, Zhang *et al.* showed that GPX4 expression level was dramatically reduced during the acute phase of ICH and that increasing GPX4 level was able to rescue neurons from secondary ferroptotic death and improve ICH outcomes in rats [53].

Ferroptosis in Parkinson's Disease

Parkinson's disease (PD) [54] is typified by death of neurons in the substantia nigra pars compacta (SNpc), which regulates motor function. PD causes rigidity, tremor, and other motor symptoms [55,56]. Apoptosis is known to be a major contributor to cell death during the progression of the disease [57]. Evidence also has shown that iron and dopamine levels in the SNpc are elevated in patients with PD [58,59]. Notably, GSH depletion, lipid peroxidation, and elevated ROS levels, which are commonly observed in patients with PD, are also features of ferroptosis [60–62]. Consistent with these findings, Ayton *et al.* reported that mice with a genetic deletion for ceruloplasmin (an iron-export ferroxidase) developed parkinsonism that was rescued by iron chelation [63]. Additionally, iron chelators have been shown to improve motor symptoms in animal models [59,63–65] and in a clinical trial [66].

Recently, ferroptosis has also been linked to PD [25]. Researchers found that ferroptosis is a key cell death pathway for dopaminergic neurons and that Fer-1 administration reduces neuronal death *in vitro* (SH-SY5Y cell line and differentiated Lund human mesencephalic [LUHMES] cells), *ex vivo* (organotypic slice cultures), and *in vivo* (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP] mouse model) [21,25]. Importantly, Do Van *et al.* claimed that ferroptosis induced by erastin in LUHMES cells was initiated by activation of MEK in a RAS-independent manner [25]. This mechanism differed from findings in other cell lines, in which the calcium chelator BAPTA and PKC inhibitors (the bisindolylmaleimide analog Bis-III and siRNA) were very effective at counteracting erastin-induced cell death [25,67]. The authors explained that the distinctive mechanisms were due to the unique metabolic feature of dopaminergic neurons [25]. A year later, Gouel *et al.* found that human platelet lysates protected the LUHMES cell line from erastin-induced ferroptosis [68]. However, they found that AKT, but not MEK or RAS, participated in erastin-induced cell death when they used U0126 and manumycin A to inhibit MEK and RAS, respectively [68]. These controversial results [25,68] in erastin-treated LUHMES cells may stem from the off-target effect of MEK inhibitor U0126. Thus, whether erastin-induced ferroptosis is RAS-dependent needs further investigation.

On the other hand, some studies have focused on how astrocytes protect against neuronal ferroptotic cell death. Astrocytes have a high capacity to store iron and prevent iron overload in neurons [69]. Astrocytes provide neurons with glutathione S-transferase Mu 2 and other antioxidants to protect them from oxidative damage. Therefore, dysregulation of astrocyte-neuron interactions and inadequate Nrf2 activation in astrocytes may lead to ferroptosis-like cell death in neurons, especially dopaminergic neurons [70,71].

Ferroptosis in Alzheimer's Disease

Alzheimer's disease (AD) is caused by the degeneration of neurons required for learning and memory [72]. Postmortem analysis of brains from AD patients shows evidence of apoptosis, which is likely responsible for a large amount of the neurodegeneration [73,74]. However, new forms of cell death are now considered to contribute to the neuronal destruction of AD because several of the degenerating processes cannot be explained by apoptosis alone and drugs targeting apoptosis are largely ineffective [75–78].

Lipid peroxidation and iron dysregulation, which are hallmarks of ferroptosis, have long been noted in AD brains [79,80]. In a recent study, mice with specific cerebral cortex and hippocampal neuronal GPX4 knockout (GPX4 brain inducible knockout, Gpx4BIKO) exhibited marked cognitive impairment in a water maze test, as well as degeneration of hippocampal neurons [72]. The authors suggested that the degenerating neurons might be undergoing ferroptosis because the level of neurodegeneration was reduced when the mice were fed a high-vitamin E diet or administered the ferroptosis inhibitor liproxstatin-1 [72]. Another study published earlier this year showed that overexpression and hyperphosphorylation of Tau induced ferroptotic neuronal death and that α -lipoic acid administration rescued neurons by downregulating iron transferrin receptor, decreasing pP38 level, and upregulating xCT and GPX4 expression [81]. These studies suggest that ferroptosis can potentially affect neurons important for learning and memory. As an extension, the findings also indicate that ferroptosis may play an important role in neuronal death during AD progression.

Ferroptosis in Huntington's Disease

Huntington's Disease (HD) [82] is yet another progressive neurodegenerative disorder that leads to rapid involuntary movements and dementia [83]. Oxidative damage [84], lipid oxidation [85], iron accumulation [86], dysregulation of GSH [87], and decreased GPX activity [88] have been noted in experimental HD animal models and in patients with HD. Delivery of iron chelators has been shown to improve cognitive function in an HD mouse [86].

To date, only one study has used a cellular model of HD (overexpression of HD-causing gene, huntingtin (htt) exon 1) to examine whether ferroptosis inhibitor Fer-1 could prevent cell death [26]. The data indicated a probable role for ferroptosis in the progressive neurodegeneration of HD. *In vivo* studies are needed to validate the role of ferroptosis in the progression of HD and its disease-specific pathologic mechanisms.

Ferroptosis in Periventricular Leukomalacia

Periventricular leukomalacia (PVL) is a form of cerebral white matter injury that affects premature infants. It is characterized by the death of developing oligodendrocytes [89]. Several studies have indicated an important role for iron in oligodendrocyte death, and some have found elevated levels of ROS biomarkers [90–93]. In addition, an abundance of lipid oxidation products typical of ferroptosis have been found in the cerebrospinal fluid of infants with white matter injuries [91]. Another study found that GSH depletion in rat

oligodendrocytes induced cell death that could be prevented with vitamin E (known to act as a ferroptosis inhibitor) [94]. All evidence indicates that ferroptosis may play a role in PVL.

To mimic PVL *in vitro*, Skouta *et al.* cultured oligodendrocytes in cystine-free medium, which depletes GSH and causes cell death [26]. Fer-1 and SRS11–92 (15-fold more potent than the parent Fer-1) fully protected oligodendrocytes from cystine deprivation [26]. These data suggest that ferroptosis is a likely mechanism oligodendrocyte death in PVL.

Ferroptosis in general neurotoxicity and aging

Neurotoxicity is defined by the Environmental Protection Agency as “an adverse change in the structure or function of the central and/or peripheral nervous system following exposure to a chemical, physical, or biological agent” [95]. In their initial classification and identification of ferroptosis, Dixon and colleagues found that using Fer-1 to inhibit ferroptosis protected rat hippocampal slice cultures from glutamate-induced neurotoxicity, suggesting a role for lipid ROS-induced cell death and most likely ferroptosis in neurotoxicity [1]. One study from Sanford-Burnham Medical Research Institute identified two potential ferroptosis inhibitors with distinct molecular mechanisms: the PI3K α inhibitor protects neuronal cells by inducing partial restoration of depleted GSH levels and accumulation of intracellular amino acids, whereas the Flt3 inhibitor prevents lipid peroxidation, a key mechanism of glutamate-mediated toxicity [96]. Another study showed that inhibition of HIF prolyl hydroxylases prevents oxidative stress-induced ferroptosis *in vitro* [41].

Levels of iron have long been known to increase with aging [97]. Additionally, iron and intra-cell iron retention have been associated with aging in diverse cell types, including neurons [98]. During the process of aging, the distribution of iron molecules changes between neurons and glial cells [99]. Iron accumulation in aged glial cells has been shown to damage neurons by increasing proinflammatory cytokines and establishing neuroinflammation [100,101]. It has been reported recently that iron retention in neurons promotes premature aging via induction of DNA damage [102]. Intracellular iron retention also has been linked to damage in the epigenome through hypomethylation and transposable elements [103,104]. The acceleration of aging via DNA damage has recently been named ferrosenescence [98].

Research into senescent cells has revealed an increase in iron accumulation, but impaired ferritinophagy, a lysosomal process that promotes ferritin degradation and ferroptosis [105]. Impaired ferritin degradation leads to a phenotype of senescent cells with elevated iron accumulation, whereby iron is effectively trapped in ferritin, creating a perceived cellular deficiency [105]. Thus, senescent cells are highly resistant to ferroptosis [105].

Ferroptosis in brain tumors

Ferroptosis was first identified in the non-small cell lung cancer cell line HT-1080 [1]. Although research has been conducted in relation to ferroptosis in many forms of cancer, little work has examined the role of ferroptosis in brain cancers. Nevertheless, Fer-1 recently was shown to have a neuroprotective role in the dopaminergic neuroblastoma cell line SH-

SY5Y under conditions of rotenone-induced oxidative stress [21]. Fer-1 was able to decrease ROS/reactive nitrogen species generated under rotenone insult, mitigate rotenone-induced α -synuclein aggregation, and even quench the stable radical from 2,2-diphenyl-1-picrylhydrazyl (DPPH) [21]. Other investigators reported that mitochondrial ferritin (FtMt) overexpression in SH-SY5Y cells significantly inhibited erastin-induced ferroptosis [106]. They also found that FtMt inhibited ferroptosis by regulating iron homeostasis, in particular by repressing cellular labile iron pool overload and altering iron-related proteins [106].

Relatively more ferroptosis-related studies have pertained to glioblastoma than to neuroblastoma. Shortly after ferroptosis was discovered, a group in Russia transplanted glioma-35 cells into mouse and found that administering iron-containing water to tumor-bearing mice before radiation therapy reduced the supercoiled DNA index on days 1 and 21 after irradiation. Additionally, it dramatically decreased the tumor volume compared with that of control on day 21 [107]. The same group repeated their study in a rat model and found consistent results that iron-containing water promoted radiation-induced tumor cell apoptosis and ferroptosis [108]. Injection of DFO into the tumor-bearing rats reduced the efficiency of this treatment but had no effect on the efficiency of radiotherapy alone [108].

From 2016 to 2018, the Savaskan group published five papers discussing the role of glutamate exchanger xCT (*SLC7a11* gene coding protein, a subunit of system x_c^-) in temozolomide (Temodal/Temcad®, TMZ)-treated glioma cells [109–113]. They reported that xCT expression correlated with the malignancy grade of brain tumor and that xCT inhibition disrupted the neurodegenerative and microenvironment-toxifying activity of gliomas [110]. TMZ efficacy can be potentiated when combined with erastin (which inhibits system x_c^-), and gliomas with high xCT expression are more vulnerable to combination treatment with erastin-TMZ [110]. In the same year, they found that high concentrations (>200 μ M) of sulfasalazine, a system x_c^- inhibitor that inhibits glioma growth [114], reduced glioma tumor volume by mechanistically inducing ferroptotic cell death in glioma cells *in vitro* [109]. Importantly, neurons and normal brain tissue barely responded to sulfasalazine, and isolated astrocytes were less sensitive than gliomas to sulfasalazine toxicity [109]. Sulfasalazine treatment did not affect experimental tumor growth, but it did reduce glioma-derived edema *in vivo* [109]. Later, they revealed that activating transcription factor 4 (ATF4) was a vital step in elevating cellular xCT and that ATF4 knockdown rendered glioma cells susceptible to erastin, sorafenib, and RSL3-induced ferroptosis [111]. Therefore, they confirmed the previous results [115] that inhibition of ATF4 may be an option for reducing glioma tumor growth and angiogenesis [111], overcoming chemoresistance from TMZ, and promoting drug efficacy in human gliomas [113]. Fan and colleagues found that, in addition to ATF4, Nrf2 overexpressed in glioma and negatively correlated with patient survival [112]. Consistent with studies in a lung carcinoma cell line [7], bladder carcinoma cells [116], and other cancer cell lines [117], they found that Nrf2 upregulated xCT expression and that activation of Nrf2 signaling promoted resistance to ferroptosis in glioma cell lines [112]. However, Berghe's group found that withaferin A induced ferroptotic cell death in high-risk neuroblastoma cells by binding to KEAP1. Consequently, it increased Nrf2 protein level and activated heme oxygenase-1 (HO-1). Elevated HO-1 induced accumulation of Fe^{2+} and subsequently induced lipid ROS and ferroptosis [118]. Moreover, withaferin A decreased GPX4 expression and induced

ferroptosis [118]. Although most researchers believe that activation of the Nrf2 signaling pathway inhibits ferroptosis [119], these results suggest that Nrf2 may play a role in promoting ferroptosis under certain conditions.

Conclusions, limitations, and further directions

The goal of this review was to discuss the role of ferroptosis, a newly identified form of cell death, in various brain disease processes, including neurologic disorders and brain tumors. Although it was first identified in cancer cells [1], ferroptosis has been shown to play an important role in the progression and toxicity of numerous neurologic diseases, including stroke, PD, and HD. As shown in Figure 2, the common ferroptotic mechanisms in brain diseases result from system x_c^- blockade, GSH depletion, GPX4 inactivity, lipoxygenase inactivation, and/or intracellular iron accumulation. These mechanisms are consistent with those seen in other disease states (renal disease, ischemic-reperfusion-related disease, and brain tumor) that can be modified by known ferroptotic inducers (glutamate, erastin, and RSL3) and inhibitors (Fer-1, liproxstatin-1, DFO, and vitamin E). However, whether MAPK, PI3K/Akt/mTOR, or KEAP1/Nrf2/HO-1 signaling pathways are common to ferroptosis-related brain diseases, or whether these signaling pathways are disease-specific, remains an open question. In addition, neurons differ from other brain cells (astrocytes and oligodendrocytes) and cells from other organs in their metabolism, dividing capacity, nerve impulse function, circuit formation, etc. Thus, when neurons are challenged with ferroptosis inducers, they could exhibit unique mechanisms that have not yet been investigated.

Ferroptosis is a unique form of regulated cell death that involves gene sets and signaling pathways distinct from those of apoptosis, necrosis, autophagy, and oxytosis [1,120]. Apoptotic cells exhibit classic features such as mitochondrial cytochrome c release, caspase activation, and chromatin fragmentation. Additionally, apoptosis can be inhibited by caspase inhibitors, and its main regulators are Bcl-2 and caspase-3 [1,2]. Cells undergoing necrosis exhibit plasma membrane permeabilization and swollen organelles. Phosphorylation of RIPK1 and RIPK3 play important roles in necrosis, and the necrotic process can be inhibited by necrostatins [1,2]. Autophagy is characterized by the formation of autophagosomes and autolysosomes, and it can be inhibited by 3-MA. Upregulation of Atg5 and Atg6 plays a vital role in the autophagy pathway [1,2]. Ferroptosis is induced by iron-dependent lipid ROS. Cells undergoing ferroptosis exhibit shrunken mitochondria and a highly intense mitochondrial membrane [1,2]. However, emerging evidence shows that ferroptosis might be a regulated necrotic cell death [4,50]. In addition, studies have found that autophagy and ferroptosis share key regulators (SLC7A11, GPX4, Nrf2, p53, HSPB1, CISD1, FANCD2, and ACSL4) [121]. Some elegant studies showed that autophagy promotes ferroptosis by degradation of ferritin in cancer cells and fibroblasts [122] and that activation of BECN1 (an important regulator in autophagy) promotes ferroptosis by directly blocking system x_c^- activity in tumor cells [123].

Oxytosis, also known as oxidative glutamate toxicity, is another form of cell death that was identified 30 years ago [124]. It is frequently compared to ferroptosis because the two pathways have similar mechanisms of lethality [120]. Oxytosis is induced by depletion of GSH that can result from high concentrations of extracellular glutamate or other reagents

that inhibit system x_c^- [2]. Mitochondrial ROS production, Ca^{2+} influx, and oxidative stress are the hallmarks of oxytosis [2]. Increasing evidence shows that oxytosis and ferroptosis share many similarities, including inducers (glutamate and RSL3), lethal mechanisms (GSH depletion and lipid ROS), a key regulator (GPX4), metal dependency (iron), and ultrastructural features (mitochondria abnormality) [1,120,125,126]. Some researchers believe that these mechanisms could be one cell death pathway with two names [120]. The data remain controversial. Dixon *et al.* claimed that ferroptosis depends on iron only [1], but recent studies showed that ferroptosis may also involve copper and calcium, as oxytosis does [120,127]. Studies have shown that most ferroptotic cells (erastin-treated MEF cells, erastin-treated BJeLR cells, and RSL3-treated MEF cells) have shrunken mitochondria with increased electron density [1,6,120]. In their review, Lewerenz *et al.* noted that both ferroptotic cells (RSL3-treated MEF cells) and oxytotic cells (glutamate-induced HT4 cells) had swollen mitochondria with outer membranes that ruptured in a time-dependent manner [120]. At this point, more studies are needed to ascertain the relationship and crosstalk between ferroptosis and other forms of cell death and to determine whether ferroptosis belongs to one of those forms of cell death.

This review is generally limited by the amount of research currently being performed on ferroptosis. Given that ferroptosis was only first identified in 2012, relatively few studies have been published on the topic. Iron accumulation that leads to cell death has been shown to contribute to many disease states, but research into the role of ferroptosis in particular is still sparse. Most of the research to date has focused on the contribution of ferroptosis to neurologic processes, but future research should also address the therapeutic benefits of inhibiting ferroptosis in brain cells that exhibit certain neurodegenerative disease characteristics and promoting ferroptosis in brain cancers. Some studies have suggested a role for GSH depletion in the progression of amyotrophic lateral sclerosis (ALS) [128], a neurodegenerative disease that causes muscular atrophy and paralysis [83]. However, conclusions have been mixed, with some researchers indicating no change in GSH levels [129,130]. At present, the role of ferroptosis in ALS is unclear and requires further research.

Epigenetic modifications are also important regulators of cellular activity and cell death. Although several miRNAs (miR-137 and miR-9) have been linked to ferroptosis [131,132], studies are needed to investigate how long non-coding RNA or circulating RNA regulates ferroptosis, and how methylation status of the CpG island and modifications of histone tails in the promoter regions of key regulators regulate ferroptosis. Furthermore, little is known about the relationship between ferroptotic cells and circulating immune system reaction. Future research could focus on how ferroptotic cells induce immune cell activation/infiltration or how surrounding immune cells regulate ferroptosis in brain cells.

We believe that ferroptosis is one of the most important cell death forms in brain diseases and that in-depth studies of ferroptosis will provide new opportunities for diagnosis and therapeutic intervention.

Acknowledgments:

We thank Dr. Fei Yang from Capital Medical University for valuable comments and suggestions. We thank Claire Levine, MS, ELS, for assistance with manuscript editing.

Funding: This review paper was supported by American Heart Association Postdoctoral Fellowship Award 17POST33660191 to XL, American Heart Association Scientist Development Grant 16SDG30980031 to XH, and the Scientific Research Program of Beijing Municipal Commission of Education (grant no. KM201710025005 to YW). JW is supported by the National Institutes of Health (R21NS102899) and a Stimulating and Advancing ACCM Research (StAAR) grant from the Department of Anesthesiology and Critical Care Medicine, John Hopkins University.

References

- Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* 149 (5):1060–1072. doi:10.1016/j.cell.2012.03.042 [PubMed: 22632970]
- Cao JY, Dixon SJ (2016) Mechanisms of ferroptosis. *Cell Mol Life Sci* 73 (11–12):2195–2209. doi: 10.1007/s00018-016-2194-1 [PubMed: 27048822]
- Yu H, Guo P, Xie X, Wang Y, Chen G (2017) Ferroptosis, a new form of cell death, and its relationships with tumorous diseases. *J Cell Mol Med* 21 (4):648–657. doi:10.1111/jcmm.13008 [PubMed: 27860262]
- Dixon SJ (2017) Ferroptosis: bug or feature? *Immunol Rev* 277 (1):150–157. doi:10.1111/immr.12533 [PubMed: 28462529]
- Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. *Cell* 156 (1–2):317–331. doi: 10.1016/j.cell.2013.12.010 [PubMed: 24439385]
- Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W (2015) Ferroptosis as a p53-mediated activity during tumour suppression. *Nature* 520 (7545):57–62. doi:10.1038/nature14344 [PubMed: 25799988]
- Chen D, Tavana O, Chu B, Erber L, Chen Y, Baer R, Gu W (2017) NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. *Mol Cell* 68 (1):224–232 e224. doi:10.1016/j.molcel.2017.09.009 [PubMed: 28985506]
- Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, Tyurin VA, Anthonymuthu TS, Kapralov AA, Amoscato AA, Mikulska-Ruminska K, Shrivastava IH, Kenny EM, Yang Q, Rosenbaum JC, Sparvero LJ, Emler DR, Wen X, Minami Y, Qu F, Watkins SC, Holman TR, VanDemark AP, Kellum JA, Bahar I, Bayir H, Kagan VE (2017) PEBP1 Wardens Ferroptosis by Enabling Lipoyxygenase Generation of Lipid Death Signals. *Cell* 171 (3):628–641 e626. doi: 10.1016/j.cell.2017.09.044 [PubMed: 29053969]
- Dolma S, Lessnick SL, Hahn WC, Stockwell BR (2003) Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. *Cancer Cell* 3 (3):285–296 [PubMed: 12676586]
- Yang WS, Stockwell BR (2008) Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. *Chem Biol* 15 (3): 234–245. doi:10.1016/j.chembiol.2008.02.010 [PubMed: 18355723]
- Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR (2016) Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. *Proc Natl Acad Sci U S A* 113 (34):E4966–4975. doi:10.1073/pnas.1603244113 [PubMed: 27506793]
- Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S, Stockwell BR (2007) RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature* 447 (7146):864–868. doi:10.1038/nature05859 [PubMed: 17568748]
- Root DE, Flaherty SP, Kelley BP, Stockwell BR (2003) Biological mechanism profiling using an annotated compound library. *Chem Biol* 10 (9):881–892 [PubMed: 14522058]
- Yang WS, Stockwell BR (2016) Ferroptosis: Death by Lipid Peroxidation. *Trends Cell Biol* 26 (3): 165–176. doi:10.1016/j.tcb.2015.10.014 [PubMed: 26653790]
- Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D (2016) Ferroptosis: process and function. *Cell Death Differ* 23 (3):369–379. doi:10.1038/cdd.2015.158 [PubMed: 26794443]

16. Liu Y, Wang W, Li Y, Xiao Y, Cheng J, Jia J (2015) The 5-Lipoxygenase Inhibitor Zileuton Confers Neuroprotection against Glutamate Oxidative Damage by Inhibiting Ferroptosis. *Biol Pharm Bull* 38 (8):1234–1239. doi:10.1248/bpb.b15-00048 [PubMed: 26235588]
17. Gaschler MM, Andia AA, Liu H, Csuka JM, Hurlocker B, Vaiana CA, Heindel DW, Zuckerman DS, Bos PH, Reznik E, Ye LF, Tyurina YY, Lin AJ, Shchepinov MS, Chan AY, Peguero-Pereira E, Fomich MA, Daniels JD, Bekish AV, Shmanai VV, Kagan VE, Mahal LK, Woerpel KA, Stockwell BR (2018) FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. *Nat Chem Biol* 14 (5):507–515. doi:10.1038/s41589-018-0031-6 [PubMed: 29610484]
18. Ma S, Dielschneider RF, Henson ES, Xiao W, Choquette TR, Blankstein AR, Chen Y, Gibson SB (2017) Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. *PLoS One* 12 (8):e0182921. doi:10.1371/journal.pone.0182921 [PubMed: 28827805]
19. Kinowaki Y, Kurata M, Ishibashi S, Ikeda M, Tatsuzawa A, Yamamoto M, Miura O, Kitagawa M, Yamamoto K (2018) Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. *Lab Invest*. doi:10.1038/s41374-017-0008-1
20. Lachaier E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, Chauffert B, Galmiche A (2014) Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. *Anticancer Res* 34 (11):6417–6422 [PubMed: 25368241]
21. Kabiraj P, Valenzuela CA, Marin JE, Ramirez DA, Mendez L, Hwang MS, Varela-Ramirez A, Fenelon K, Narayan M, Skouta R (2015) The neuroprotective role of ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells. *Protein J* 34 (5):349–358. doi:10.1007/s10930-015-9629-7 [PubMed: 26385697]
22. Kim SE, Zhang L, Ma K, Riegman M, Chen F, Ingold I, Conrad M, Turker MZ, Gao M, Jiang X, Monette S, Pauliah M, Gonen M, Zanzonico P, Quinn T, Wiesner U, Bradbury MS, Overholzer M (2016) Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. *Nat Nanotechnol* 11 (11):977–985. doi:10.1038/nnano.2016.164 [PubMed: 27668796]
23. Li Q, Han X, Lan X, Gao Y, Wan J, Durham F, Cheng T, Yang J, Wang Z, Jiang C, Ying M, Koehler RC, Stockwell BR, Wang J (2017) Inhibition of neuronal ferroptosis protects hemorrhagic brain. *JCI Insight* 2 (7):e90777. doi:10.1172/jci.insight.90777 [PubMed: 28405617]
24. Chang CF, Cho S, Wang J (2014) (–)-Epicatechin protects hemorrhagic brain via synergistic Nrf2 pathways. *Ann Clin Transl Neurol* 1 (4):258–271. doi:10.1002/acn3.54 [PubMed: 24741667]
25. Do Van B, Gouel F, Jonneaux A, Timmerman K, Gele P, Petrault M, Bastide M, Laloux C, Moreau C, Bordet R, Devos D, Devedjian JC (2016) Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. *Neurobiol Dis* 94:169–178. doi:10.1016/j.nbd.2016.05.011 [PubMed: 27189756]
26. Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A, Stockwell BR (2014) Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. *J Am Chem Soc* 136 (12):4551–4556. doi:10.1021/ja411006a [PubMed: 24592866]
27. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Statistics C, Stroke Statistics S (2017) Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation* 135 (10):e146–e603. doi:10.1161/CIR.0000000000000485 [PubMed: 28122885]
28. Au A, Griffiths LR, Irene L, Kooi CW, Wei LK (2017) The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic stroke: Evidence from a meta-analysis. *Atherosclerosis* 265:60–70. doi:10.1016/j.atherosclerosis.2017.08.003 [PubMed: 28865324]
29. Brouns R, De Deyn PP (2009) The complexity of neurobiological processes in acute ischemic stroke. *Clin Neurol Neurosurg* 111 (6):483–495. doi:10.1016/j.clineuro.2009.04.001 [PubMed: 19446389]

30. Dietrich RB, Bradley WG Jr. (1988) Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. *Radiology* 168 (1):203–206. doi:10.1148/radiology.168.1.3380958 [PubMed: 3380958]
31. Lipscomb DC, Gorman LG, Traystman RJ, Hurn PD (1998) Low molecular weight iron in cerebral ischemic acidosis in vivo. *Stroke* 29 (2):487–492; discussion 493 [PubMed: 9472894]
32. Ding H, Yan CZ, Shi H, Zhao YS, Chang SY, Yu P, Wu WS, Zhao CY, Chang YZ, Duan XL (2011) Hepcidin is involved in iron regulation in the ischemic brain. *PLoS One* 6 (9):e25324. doi:10.1371/journal.pone.0025324 [PubMed: 21957487]
33. Park UJ, Lee YA, Won SM, Lee JH, Kang SH, Springer JE, Lee YB, Gwag BJ (2011) Blood-derived iron mediates free radical production and neuronal death in the hippocampal CA1 area following transient forebrain ischemia in rat. *Acta Neuropathol* 121 (4):459–473. doi:10.1007/s00401-010-0785-8 [PubMed: 21120509]
34. Fang KM, Cheng FC, Huang YL, Chung SY, Jian ZY, Lin MC (2013) Trace element, antioxidant activity, and lipid peroxidation levels in brain cortex of gerbils after cerebral ischemic injury. *Biol Trace Elem Res* 152 (1):66–74. doi:10.1007/s12011-012-9596-1 [PubMed: 23334863]
35. Kondo Y, Asanuma M, Nishibayashi S, Iwata E, Ogawa N (1997) Late-onset lipid peroxidation and neuronal cell death following transient forebrain ischemia in rat brain. *Brain Res* 772 (1–2):37–44 [PubMed: 9406953]
36. Kondo Y, Ogawa N, Asanuma M, Ota Z, Mori A (1995) Regional differences in late-onset iron deposition, ferritin, transferrin, astrocyte proliferation, and microglial activation after transient forebrain ischemia in rat brain. *J Cereb Blood Flow Metab* 15 (2):216–226. doi:10.1038/jcbfm.1995.27 [PubMed: 7860655]
37. Patt A, Horesh IR, Berger EM, Harken AH, Repine JE (1990) Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. *J Pediatr Surg* 25 (2):224–227; discussion 227–228 [PubMed: 2303992]
38. Davis S, Helfaer MA, Traystman RJ, Hurn PD (1997) Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemia in dogs. *Stroke* 28 (1):198–204; discussion 204–195 [PubMed: 8996512]
39. Prass K, Ruscher K, Karsch M, Isaev N, Megow D, Priller J, Scharff A, Dirnagl U, Meisel A (2002) Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. *J Cereb Blood Flow Metab* 22 (5):520–525. doi:10.1097/00004647-200205000-00003 [PubMed: 11973424]
40. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH 2nd, Panter SS (2009) Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. *J Pharmacol Exp Ther* 330 (3):679–686. doi:10.1124/jpet.108.149807 [PubMed: 19509317]
41. Speer RE, Karuppagounder SS, Basso M, Sleiman SF, Kumar A, Brand D, Smirnova N, Gazaryan I, Khim SJ, Ratan RR (2013) Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke. *Free Radic Biol Med* 62:26–36. doi:10.1016/j.freeradbiomed.2013.01.026 [PubMed: 23376032]
42. Tuo QZ, Lei P, Jackman KA, Li XL, Xiong H, Li XL, Liuyang ZY, Roisman L, Zhang ST, Ayton S, Wang Q, Crouch PJ, Ganio K, Wang XC, Pei L, Adlard PA, Lu YM, Cappai R, Wang JZ, Liu R, Bush AI (2017) Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. *Mol Psychiatry* 22 (11):1520–1530. doi:10.1038/mp.2017.171 [PubMed: 28886009]
43. Li Q, Wan J, Lan X, Han X, Wang Z, Wang J (2017) Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice. *J Cereb Blood Flow Metab* 271678X17709186. doi:10.1177/0271678X17709186
44. Qureshi AI, Suri MF, Ostrow PT, Kim SH, Ali Z, Shatla AA, Guterman LR, Hopkins LN (2003) Apoptosis as a form of cell death in intracerebral hemorrhage. *Neurosurgery* 52 (5):1041–1047; discussion 1047–1048 [PubMed: 12699545]
45. Hickenbottom SL, Grotta JC, Strong R, Denner LA, Aronowski J (1999) Nuclear factor-kappaB and cell death after experimental intracerebral hemorrhage in rats. *Stroke* 30 (11):2472–2477; discussion 2477–2478 [PubMed: 10548686]

46. Qureshi AI, Ling GS, Khan J, Suri MF, Miskolczi L, Guterman LR, Hopkins LN (2001) Quantitative analysis of injured, necrotic, and apoptotic cells in a new experimental model of intracerebral hemorrhage. *Crit Care Med* 29 (1):152–157 [PubMed: 11176176]
47. Wang KY, Wu CH, Zhou LY, Yan XH, Yang RL, Liao LM, Ge XM, Liao YS, Li SJ, Li HZ, Gao LL, Lin JS, Huang SY (2015) Ultrastructural changes of brain tissues surrounding hematomas after intracerebral hemorrhage. *Eur Neurol* 74 (1–2):28–35. doi:10.1159/000434631 [PubMed: 26139100]
48. Wu H, Wu T, Li M, Wang J (2012) Efficacy of the lipid-soluble iron chelator 2,2'-dipyridyl against hemorrhagic brain injury. *Neurobiol Dis* 45 (1):388–394. doi:10.1016/j.nbd.2011.08.028 [PubMed: 21930208]
49. Wu H, Wu T, Xu X, Wang J, Wang J (2011) Iron toxicity in mice with collagenase-induced intracerebral hemorrhage. *J Cereb Blood Flow Metab* 31 (5):1243–1250. doi:10.1038/jcbfm.2010.209 [PubMed: 21102602]
50. Zille M, Karuppagounder SS, Chen Y, Gough PJ, Bertin J, Finger J, Milner TA, Jonas EA, Ratan RR (2017) Neuronal Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis and Necroptosis. *Stroke* 48 (4):1033–1043. doi:10.1161/STROKEAHA.116.015609 [PubMed: 28250197]
51. Li Q, Weiland A, Chen X, Lan X, Han X, Durham F, Liu X, Wan J, Ziai WC, Hanley DF, Wang J (2018) Ultrastructural Characteristics of Neuronal Death and White Matter Injury in Mouse Brain Tissues After Intracerebral Hemorrhage: Coexistence of Ferroptosis, Autophagy, and Necrosis. *Front Neurol* 9:581. doi:10.3389/fneur.2018.00581 [PubMed: 30065697]
52. Gao M, Monian P, Quadri N, Ramasamy R, Jiang X (2015) Glutaminolysis and transferrin regulate ferroptosis. *Mol Cell* 59 (2):298–308. doi:10.1016/j.molcel.2015.06.011 [PubMed: 26166707]
53. Zhang Z, Wu Y, Yuan S, Zhang P, Zhang J, Li H, Li X, Shen H, Wang Z, Chen G (2018) Glutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhage. *Brain Res*. doi:10.1016/j.brainres.2018.09.012
54. Pichler I, Del Greco MF, Gogele M, Lill CM, Bertram L, Do CB, Eriksson N, Foroud T, Myers RH, Consortium PG, Nalls M, Keller MF, International Parkinson's Disease Genomics C, Wellcome Trust Case Control C, Benyamin B, Whitfield JB, Genetics of Iron Status C, Pramstaller PP, Hicks AA, Thompson JR, Minelli C (2013) Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. *PLoS Med* 10 (6):e1001462. doi:10.1371/journal.pmed.1001462 [PubMed: 23750121]
55. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain* 114 (Pt 5):2283–2301 [PubMed: 1933245]
56. Rinne JO, Rummukainen J, Paljarvi L, Sako E, Molsa P, Rinne UK (1989) Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia. *Prog Clin Biol Res* 317:325–332 [PubMed: 2602422]
57. Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. *Cell Tissue Res* 318 (1):215–224. doi:10.1007/s00441-004-0938-y [PubMed: 15503155]
58. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in postmortem parkinsonian brain. *Lancet* 2 (8569):1219–1220 [PubMed: 2890848]
59. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. *Nat Med* 18 (2):291–295. doi:10.1038/nm.2613 [PubMed: 22286308]
60. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. *Ann Neurol* 36 (3):348–355. doi:10.1002/ana.410360305 [PubMed: 8080242]
61. Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1986) Lipid peroxidation as cause of nigral cell death in Parkinson's disease. *Lancet* 2 (8507):639–640
62. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker WD Jr., Bennett JP Jr. (1997) Elevated reactive oxygen species and antioxidant enzyme activities in

- animal and cellular models of Parkinson's disease. *Biochim Biophys Acta* 1362 (1):77–86 [PubMed: 9434102]
63. Ayton S, Lei P, Duce JA, Wong BX, Sedjahtera A, Adlard PA, Bush AI, Finkelstein DI (2013) Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. *Ann Neurol* 73 (4): 554–559. doi:10.1002/ana.23817 [PubMed: 23424051]
 64. Ayton S, Lei P, Hare DJ, Duce JA, George JL, Adlard PA, McLean C, Rogers JT, Cherny RA, Finkelstein DI, Bush AI (2015) Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. *J Neurosci* 35 (8):3591–3597. doi:10.1523/JNEUROSCI.3439-14.2015 [PubMed: 25716857]
 65. Lei P, Ayton S, Appukuttan AT, Volitakis I, Adlard PA, Finkelstein DI, Bush AI (2015) Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. *Neurobiol Dis* 81:168–175. doi:10.1016/j.nbd.2015.03.015 [PubMed: 25796563]
 66. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garcon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonniere B, Strubi-Vuillaume I, Zahr N, Destee A, Corvol JC, Poltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R (2014) Targeting chelatable iron as a therapeutic modality in Parkinson's disease. *Antioxid Redox Signal* 21 (2):195–210. doi:10.1089/ars.2013.5593 [PubMed: 24251381]
 67. Zhang HM, Su Q (2014) PKC in developmental hypothyroid rat brain. *Neurol Sci* 35 (8):1161–1166. doi:10.1007/s10072-014-1716-6 [PubMed: 24682728]
 68. Gouel F, Do Van B, Chou ML, Jonneaux A, Moreau C, Bordet R, Burnouf T, Devedjian JC, Devos D (2017) The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways. *J Tissue Eng Regen Med* 11 (11):3236–3240. doi:10.1002/term.2222 [PubMed: 27943621]
 69. Codazzi F, Pelizzoni I, Zacchetti D, Grohovaz F (2015) Iron entry in neurons and astrocytes: a link with synaptic activity. *Front Mol Neurosci* 8:18. doi:10.3389/fnmol.2015.00018 [PubMed: 26089776]
 70. Ishii T, Warabi E, Mann GE (2018) Circadian control of BDNF-mediated Nrf2 activation in astrocytes protects dopaminergic neurons from ferroptosis. *Free Radic Biol Med*. doi:10.1016/j.freeradbiomed.2018.09.002
 71. Cui Z, Zhong Z, Yang Y, Wang B, Sun Y, Sun Q, Yang GY, Bian L (2016) Ferrous Iron Induces Nrf2 Expression in Mouse Brain Astrocytes to Prevent Neurotoxicity. *J Biochem Mol Toxicol* 30 (8):396–403. doi:10.1002/jbt.21803 [PubMed: 27037625]
 72. Hambright WS, Fonseca RS, Chen L, Na R, Ran Q (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. *Redox Biol* 12:8–17. doi:10.1016/j.redox.2017.01.021 [PubMed: 28212525]
 73. Cotman CW, Anderson AJ (1995) A potential role for apoptosis in neurodegeneration and Alzheimer's disease. *Mol Neurobiol* 10 (1):19–45. doi:10.1007/BF02740836 [PubMed: 7598831]
 74. Mattson MP (2006) Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. *Antioxid Redox Signal* 8 (11–12):1997–2006. doi:10.1089/ars.2006.8.1997 [PubMed: 17034345]
 75. Khandelwal PJ, Herman AM, Moussa CE (2011) Inflammation in the early stages of neurodegenerative pathology. *J Neuroimmunol* 238 (1–2):1–11. doi:10.1016/j.jneuroim.2011.07.002 [PubMed: 21820744]
 76. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. *Biochim Biophys Acta* 1842 (8):1240–1247. doi:10.1016/j.bbadis.2013.10.015 [PubMed: 24189435]
 77. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R, Western ALSWG (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. *Lancet Neurol* 6 (12):1045–1053. doi:10.1016/S1474-4422(07)70270-3 [PubMed: 17980667]
 78. Parkinson Study Group PI (2007) Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. *Neurology* 69 (15):1480–1490. doi:10.1212/01.wnl.0000277648.63931.c0 [PubMed: 17881719]

79. Pratico D, Sung S (2004) Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. *J Alzheimers Dis* 6 (2):171–175 [PubMed: 15096701]
80. Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, Zhu X (2007) Iron: the Redox-active center of oxidative stress in Alzheimer disease. *Neurochem Res* 32 (10):1640–1645. doi: 10.1007/s11064-007-9360-7 [PubMed: 17508283]
81. Zhang YH, Wang DW, Xu SF, Zhang S, Fan YG, Yang YY, Guo SQ, Wang S, Guo T, Wang ZY, Guo C (2018) alpha-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice. *Redox Biol* 14:535–548. doi:10.1016/j.redox.2017.11.001 [PubMed: 29126071]
82. Alipanahzadeh H, Soleimani M, Soleimani Asl S, Pourheydar B, Nikkiah A, Mehdizadeh M (2014) Transforming growth factor-alpha improves memory impairment and neurogenesis following ischemia reperfusion. *Cell J* 16 (3):315–324 [PubMed: 24611146]
83. Johnson WM, Wilson-Delfosse AL, Mielal JJ (2012) Dysregulation of glutathione homeostasis in neurodegenerative diseases. *Nutrients* 4 (10):1399–1440. doi:10.3390/nu4101399 [PubMed: 23201762]
84. Browne SE, Ferrante RJ, Beal MF (1999) Oxidative stress in Huntington's disease. *Brain Pathol* 9 (1):147–163 [PubMed: 9989457]
85. Lee J, Kosaras B, Del Signore SJ, Cormier K, McKee A, Ratan RR, Kowall NW, Ryu H (2011) Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. *Acta Neuropathol* 121 (4):487–498. doi:10.1007/s00401-010-0788-5 [PubMed: 21161248]
86. Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, Volitakis I, Bush AI, Hersch S, Fox JH (2013) Iron accumulates in Huntington's disease neurons: protection by deferoxamine. *PLoS One* 8 (10):e77023. doi:10.1371/journal.pone.0077023 [PubMed: 24146952]
87. Klepac N, Relja M, Klepac R, Hecimovic S, Babic T, Trkulja V (2007) Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study. *J Neurol* 254 (12):1676–1683. doi:10.1007/s00415-007-0611-y [PubMed: 17990062]
88. Chen CM, Wu YR, Cheng ML, Liu JL, Lee YM, Lee PW, Soong BW, Chiu DT (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. *Biochem Biophys Res Commun* 359 (2):335–340. doi:10.1016/j.bbrc.2007.05.093 [PubMed: 17543886]
89. Volpe JJ, Kinney HC, Jensen FE, Rosenberg PA (2011) Reprint of “The developing oligodendrocyte: key cellular target in brain injury in the premature infant”. *Int J Dev Neurosci* 29 (6):565–582. doi:10.1016/j.ijdevneu.2011.07.008 [PubMed: 21802506]
90. Back SA, Luo NL, Mallinson RA, O'Malley JP, Wallen LD, Frei B, Morrow JD, Petito CK, Roberts CT Jr., Murdoch GH, Montine TJ (2005) Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. *Ann Neurol* 58 (1):108–120. doi:10.1002/ana.20530 [PubMed: 15984031]
91. Inder T, Mocatta T, Darlow B, Spencer C, Volpe JJ, Winterbourn C (2002) Elevated free radical products in the cerebrospinal fluid of VLBW infants with cerebral white matter injury. *Pediatr Res* 52 (2):213–218. doi:10.1203/00006450-200208000-00013 [PubMed: 12149498]
92. Brault S, Martinez-Bermudez AK, Roberts J 2nd, Cui QL, Fragoso G, Hemdan S, Liu HN, Gobeil F Jr., Quiniou C, Kermorvant-Duchemin E, Lachance C, Almazan G, Varma DR, Chemtob S (2004) Cytotoxicity of the E(2)-isoprostane 15-E(2t)-IsoP on oligodendrocyte progenitors. *Free Radic Biol Med* 37 (3):358–366. doi:10.1016/j.freeradbiomed.2004.05.007 [PubMed: 15223069]
93. Welin AK, Svedin P, Lapatto R, Sultan B, Hagberg H, Gressens P, Kjellmer I, Mallard C (2007) Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. *Pediatr Res* 61 (2):153–158. doi:10.1203/01.pdr.0000252546.20451.1a [PubMed: 17237714]
94. Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ (1998) Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. *J Neurosci* 18 (16):6241–6253 [PubMed: 9698317]

95. Roberts RA, Aschner M, Calligaro D, Guilarte TR, Hanig JP, Herr DW, Hudzik TJ, Jeromin A, Kallman MJ, Liachenko S, Lynch JJ 3rd, Miller DB, Moser VC, O'Callaghan JP, Slikker W Jr., Paule MG (2015) Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward. *Toxicol Sci* 148 (2):332–340. doi:10.1093/toxsci/kfv188 [PubMed: 26609132]
96. Kang Y, Tiziani S, Park G, Kaul M, Paternostro G (2014) Cellular protection using Flt3 and PI3Kalpha inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity. *Nat Commun* 5:3672. doi:10.1038/ncomms4672 [PubMed: 24739485]
97. Hagemeyer J, Geurts JJ, Zivadinov R (2012) Brain iron accumulation in aging and neurodegenerative disorders. *Expert Rev Neurother* 12 (12):1467–1480. doi:10.1586/ern.12.128 [PubMed: 23237353]
98. Sfera A, Bullock K, Price A, Inderias L, Osorio C (2017) Ferrosenescence: The iron age of neurodegeneration? *Mech Ageing Dev.* doi:10.1016/j.mad.2017.11.012
99. Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. *J Neurochem* 76 (6):1766–1773 [PubMed: 11259494]
100. Pedini M, De Meo G, Ricci A, Bastianini L, Jacquignon P (1990) New heterocyclic derivatives of benzimidazole with germicidal activity--VII--2-(5'-nitro-2'-furyl or 2'-thienyl) benzimidazoles with different substituents in the 5-position. *Farmaco* 45 (3):303–312 [PubMed: 2200421]
101. Xu J, Jia Z, Knutson MD, Leeuwenburgh C (2012) Impaired iron status in aging research. *Int J Mol Sci* 13 (2):2368–2386. doi:10.3390/ijms13022368 [PubMed: 22408459]
102. Mollet IG, Patel D, Govani FS, Giess A, Paschalaki K, Periyasamy M, Lidington EC, Mason JC, Jones MD, Game L, Ali S, Shovlin CL (2016) Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes. *PLoS One* 11 (2):e0147990. doi:10.1371/journal.pone.0147990 [PubMed: 26866805]
103. Sturm A, Ivics Z, Vellai T (2015) The mechanism of ageing: primary role of transposable elements in genome disintegration. *Cell Mol Life Sci* 72 (10):1839–1847. doi:10.1007/s00018-015-1896-0 [PubMed: 25837999]
104. Orr WC (2016) Tightening the connection between transposable element mobilization and aging. *Proc Natl Acad Sci U S A* 113 (40):11069–11070. doi:10.1073/pnas.1613350113 [PubMed: 27663733]
105. Masaldan S, Clatworthy SAS, Gamell C, Meggyesy PM, Rigopoulos AT, Haupt S, Haupt Y, Denoyer D, Adlard PA, Bush AI, Cater MA (2018) Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. *Redox Biol* 14:100–115. doi:10.1016/j.redox.2017.08.015 [PubMed: 28888202]
106. Wang YQ, Chang SY, Wu Q, Gou YJ, Jia L, Cui YM, Yu P, Shi ZH, Wu WS, Gao G, Chang YZ (2016) The Protective Role of Mitochondrial Ferritin on Erastin-Induced Ferroptosis. *Front Aging Neurosci* 8:308. doi:10.3389/fnagi.2016.00308 [PubMed: 28066232]
107. Ivanov SD, Semenov AL, Mikhelson VM, Kovan'ko EG, Iamshanov VA (2013) [Effects of iron ion additional introduction in radiation therapy of tumor-bearing animals]. *Radiats Biol Radioecol* 53 (3):296–303 [PubMed: 24450211]
108. Ivanov SD, Semenov AL, Kovan'ko EG, Yamshanov VA (2015) Effects of iron ions and iron chelation on the efficiency of experimental radiotherapy of animals with gliomas. *Bull Exp Biol Med* 158 (6):800–803. doi:10.1007/s10517-015-2865-1 [PubMed: 25896595]
109. Sehm T, Fan Z, Ghoochani A, Rauh M, Engelhorn T, Minakaki G, Dorfler A, Klucken J, Buchfelder M, Eyupoglu IY, Savaskan N (2016) Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. *Oncotarget* 7 (24):36021–36033. doi:10.18632/oncotarget.8651 [PubMed: 27074570]
110. Sehm T, Rauh M, Wiendieck K, Buchfelder M, Eyupoglu IY, Savaskan NE (2016) Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis. *Oncotarget* 7 (46):74630–74647. doi:10.18632/oncotarget.11858 [PubMed: 27612422]

111. Chen D, Fan Z, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan N (2017) ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner. *Oncogene* 36 (40):5593–5608. doi:10.1038/onc.2017.146 [PubMed: 28553953]
112. Fan Z, Wirth AK, Chen D, Wruck CJ, Rauh M, Buchfelder M, Savaskan N (2017) Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. *Oncogenesis* 6 (8):e371. doi:10.1038/oncsis.2017.65 [PubMed: 28805788]
113. Chen D, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan N (2017) The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas. *Oncotarget* 8 (31):51164–51176. doi:10.18632/oncotarget.17737 [PubMed: 28881638]
114. Chung WJ, Sontheimer H (2009) Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. *J Neurochem* 110 (1):182–193. doi:10.1111/j.1471-4159.2009.06129.x [PubMed: 19457125]
115. Lewerenz J, Baxter P, Kassubek R, Albrecht P, Van Liefferinge J, Westhoff MA, Halatsch ME, Karpel-Massler G, Meakin PJ, Hayes JD, Aronica E, Smolders I, Ludolph AC, Methner A, Conrad M, Massie A, Hardingham GE, Maher P (2014) Phosphoinositide 3-kinases upregulate system xc(–) via eukaryotic initiation factor 2alpha and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy. *Antioxid Redox Signal* 20 (18):2907–2922. doi:10.1089/ars.2013.5455 [PubMed: 24219064]
116. Ye P, Mimura J, Okada T, Sato H, Liu T, Maruyama A, Ohyama C, Itoh K (2014) Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. *Mol Cell Biol* 34 (18):3421–3434. doi:10.1128/MCB.00221-14 [PubMed: 25002527]
117. Habib E, Linher-Melville K, Lin HX, Singh G (2015) Expression of xCT and activity of system xc(–) are regulated by NRF2 in human breast cancer cells in response to oxidative stress. *Redox Biol* 5:33–42. doi:10.1016/j.redox.2015.03.003 [PubMed: 25827424]
118. Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, Bayir H, Abhari BA, Angeli JPF, Choi SM, Meul E, Heynink K, Declerck K, Chirumamilla CS, Lahtela-Kakkonen M, Van Camp G, Krysko DV, Ekert PG, Fulda S, De Geest BG, Conrad M, Kagan VE, Berghe WV, Vandenabeele P, Berghe TV (2018) Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. *J Clin Invest*. doi:10.1172/JCI99032
119. Abdalkader M, Lampinen R, Kanninen KM, Malm TM, Liddell JR (2018) Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration. *Front Neurosci* 12:466. doi:10.3389/fnins.2018.00466 [PubMed: 30042655]
120. Lewerenz J, Ates G, Methner A, Conrad M, Maher P (2018) Oxytosis/Ferroptosis-(Re-) Emerging Roles for Oxidative Stress-Dependent Non-apoptotic Cell Death in Diseases of the Central Nervous System. *Front Neurosci* 12:214. doi:10.3389/fnins.2018.00214 [PubMed: 29731704]
121. Kang R, Tang D (2017) Autophagy and Ferroptosis - What's the Connection? *Curr Pathobiol Rep* 5 (2):153–159. doi:10.1007/s40139-017-0139-5 [PubMed: 29038744]
122. Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, 3rd, Kang R, Tang D (2016) Autophagy promotes ferroptosis by degradation of ferritin. *Autophagy*:1–4. doi:10.1080/15548627.2016.1187366 [PubMed: 26799652]
123. Song X, Zhu S, Chen P, Hou W, Wen Q, Liu J, Xie Y, Liu J, Klionsky DJ, Kroemer G, Lotze MT, Zeh HJ, Kang R, Tang D (2018) AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc(–) Activity. *Curr Biol* 28 (15):2388–2399 e2385. doi:10.1016/j.cub.2018.05.094 [PubMed: 30057310]
124. Murphy TH, Malouf AT, Sastre A, Schnaar RL, Coyle JT (1988) Calcium-dependent glutamate cytotoxicity in a neuronal cell line. *Brain Res* 444 (2):325–332 [PubMed: 2896063]
125. Miyamoto M, Murphy TH, Schnaar RL, Coyle JT (1989) Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. *J Pharmacol Exp Ther* 250 (3):1132–1140 [PubMed: 2778712]
126. Maher P (2018) Potentiation of glutathione loss and nerve cell death by the transition metals iron and copper: Implications for age-related neurodegenerative diseases. *Free Radic Biol Med* 115:92–104. doi:10.1016/j.freeradbiomed.2017.11.015 [PubMed: 29170091]

127. Maher P, van Leyen K, Dey PN, Honrath B, Dolga A, Methner A (2018) The role of Ca(2+) in cell death caused by oxidative glutamate toxicity and ferroptosis. *Cell Calcium* 70:47–55. doi: 10.1016/j.ceca.2017.05.007 [PubMed: 28545724]
128. Babu GN, Kumar A, Chandra R, Puri SK, Singh RL, Kalita J, Misra UK (2008) Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. *Neurochem Int* 52 (6):1284–1289. doi:10.1016/j.neuint.2008.01.009 [PubMed: 18308427]
129. Nissen C, Gratwohl A, Speck B (1991) Management of aplastic anemia. *Eur J Haematol* 46 (4): 193–197 [PubMed: 2015873]
130. Bonnefont-Rousselot D, Lacomblez L, Jaudon M, Lepage S, Salachas F, Bensimon G, Bizard C, Doppler V, Delattre J, Meininger V (2000) Blood oxidative stress in amyotrophic lateral sclerosis. *J Neurol Sci* 178 (1):57–62 [PubMed: 11018250]
131. Luo M, Wu L, Zhang K, Wang H, Zhang T, Gutierrez L, O'Connell D, Zhang P, Li Y, Gao T, Ren W, Yang Y (2018) miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. *Cell Death Differ* 25 (8):1457–1472. doi:10.1038/s41418-017-0053-8 [PubMed: 29348676]
132. Zhang K, Wu L, Zhang P, Luo M, Du J, Gao T, O'Connell D, Wang G, Wang H, Yang Y (2018) miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma. *Mol Carcinog*. doi:10.1002/mc.22878
133. Larraufie MH, Yang WS, Jiang E, Thomas AG, Slusher BS, Stockwell BR (2015) Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. *Bioorg Med Chem Lett* 25 (21):4787–4792. doi:10.1016/j.bmcl.2015.07.018 [PubMed: 26231156]
134. Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, Stockwell BR (2014) Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *Elife* 3:e02523. doi:10.7554/eLife.02523 [PubMed: 24844246]
135. Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, Francois C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A (2015) The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. *Cancer Lett* 356 (2 Pt B):971–977. doi:10.1016/j.canlet.2014.11.014 [PubMed: 25444922]
136. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T (2011) Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. *Proc Natl Acad Sci U S A* 108 (21):8773–8778. doi: 10.1073/pnas.1105941108 [PubMed: 21555567]
137. Chen L, Li X, Liu L, Yu B, Xue Y, Liu Y (2015) Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-gamma-lyase function. *Oncol Rep* 33 (3): 1465–1474. doi:10.3892/or.2015.3712 [PubMed: 25585997]
138. Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, Superti-Furga G, Stockwell BR (2015) Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. *ACS Chem Biol* 10 (7):1604–1609. doi:10.1021/acscmbio.5b00245 [PubMed: 25965523]
139. Bellinger FP, Raman AV, Rueli RH, Bellinger MT, Dewing AS, Seale LA, Andres MA, Uyehara-Lock JH, White LR, Ross GW, Berry MJ (2012) Changes in selenoprotein P in substantia nigra and putamen in Parkinson's disease. *J Parkinsons Dis* 2 (2):115–126. doi:10.3233/JPD-2012-11052 [PubMed: 23268326]
140. Paz-y-Mino C, Carrera C, Lopez-Cortes A, Munoz MJ, Cumbal N, Castro B, Cabrera A, Sanchez ME (2010) Genetic polymorphisms in apolipoprotein E and glutathione peroxidase 1 genes in the Ecuadorian population affected with Alzheimer's disease. *Am J Med Sci* 340 (5):373–377. doi: 10.1097/MAJ.0b013e3181e93475 [PubMed: 20724907]
141. Usarek E, Gajewska B, Kazmierczak B, Kuzma M, Dziewulska D, Baranczyk-Kuzma A (2005) A study of glutathione S-transferase pi expression in central nervous system of subjects with amyotrophic lateral sclerosis using RNA extraction from formalin-fixed, paraffin-embedded material. *Neurochem Res* 30 (8):1003–1007. doi:10.1007/s11064-005-6771-1 [PubMed: 16258849]

142. Abrams RP, Carroll WL, Woerpel KA (2016) Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells. *ACS Chem Biol* 11 (5):1305–1312. doi:10.1021/acscchembio.5b00900 [PubMed: 26797166]
143. Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR (2015) Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. *Oncoscience* 2 (5):517–532. doi:10.18632/oncoscience.160 [PubMed: 26097885]
144. Sultana R, Perluigi M, Butterfield DA (2013) Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. *Free Radic Biol Med* 62:157–169. doi:10.1016/j.freeradbiomed.2012.09.027 [PubMed: 23044265]
145. Miller RL, James-Kracke M, Sun GY, Sun AY (2009) Oxidative and inflammatory pathways in Parkinson's disease. *Neurochem Res* 34 (1):55–65. doi:10.1007/s11064-008-9656-2 [PubMed: 18363100]
146. Jin YN, Johnson GV (2010) The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. *J Bioenerg Biomembr* 42 (3):199–205. doi:10.1007/s10863-010-9286-7 [PubMed: 20556492]
147. Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Jaronen M, Arens E, Akerman K, Chan PH, Koistinaho J (2008) Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. *J Biol Chem* 283 (13):8446–8452. doi:10.1074/jbc.M706111200 [PubMed: 18171673]
148. Armstrong JS, Khdour O, Hecht SM (2010) Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question. *FASEB J* 24 (7):2152–2163. doi:10.1096/fj.09-143222 [PubMed: 20219987]
149. Wu C, Zhao W, Yu J, Li S, Lin L, Chen X (2018) Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells. *Sci Rep* 8 (1):574. doi:10.1038/s41598-017-18935-1 [PubMed: 29330409]
150. Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, Lorient MA, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JI, Ritz B (2014) Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin. *Neurobiol Dis* 62:172–178. doi:10.1016/j.nbd.2013.09.019 [PubMed: 24121126]
151. Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, Wang X, Bell DA, Li X, Garlick DS, Liu Q, Hollstein M, George DL, Murphy ME (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. *Genes Dev* 30 (8):918–930. doi:10.1101/gad.275891.115 [PubMed: 27034505]
152. Ooko E, Saeed ME, Kadioglu O, Sarvi S, Colak M, Elmasaoudi K, Janah R, Greten HJ, Efferth T (2015) Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. *Phytomedicine* 22 (11):1045–1054. doi:10.1016/j.phymed.2015.08.002 [PubMed: 26407947]
153. Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Cai J, Wei X, Bazzan AJ, Zhong L, Bowen B, Intenzo CM, Iacovitti L, Newberg AB (2016) N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data. *PLoS One* 11 (6):e0157602. doi:10.1371/journal.pone.0157602 [PubMed: 27309537]
154. Cristalli DO, Arnal N, Marra FA, de Alaniz MJ, Marra CA (2012) Peripheral markers in neurodegenerative patients and their first-degree relatives. *J Neurol Sci* 314 (1–2):48–56. doi:10.1016/j.jns.2011.11.001 [PubMed: 22113180]
155. Piemonte F, Pastore A, Tozzi G, Tagliacozzi D, Santorelli FM, Carrozzo R, Casali C, Damiano M, Federici G, Bertini E (2001) Glutathione in blood of patients with Friedreich's ataxia. *Eur J Clin Invest* 31 (11):1007–1011 [PubMed: 11737244]
156. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick JE, Schimmer AD (2009) Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. *Blood* 114 (14):3064–3073. doi:10.1182/blood-2009-03-209965 [PubMed: 19589922]
157. Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, Prokai A, Zuchtriegel G, Krombach F, Welz PS, Weinlich R, Vanden Berghe T, Vandenabeele P, Pasparakis M, Bleich M, Weinberg JM, Reichel CA, Brasen JH, Kunzendorf U, Anders HJ, Stockwell BR, Green DR,

- Krautwald S (2014) Synchronized renal tubular cell death involves ferroptosis. *Proc Natl Acad Sci U S A* 111 (47):16836–16841. doi:10.1073/pnas.1415518111 [PubMed: 25385600]
158. Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, Basavarajappa D, Radmark O, Kobayashi S, Seibt T, Beck H, Neff F, Esposito I, Wanke R, Forster H, Yefremova O, Heinrichmeyer M, Bornkamm GW, Geissler EK, Thomas SB, Stockwell BR, O'Donnell VB, Kagan VE, Schick JA, Conrad M (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. *Nat Cell Biol* 16 (12):1180–1191. doi:10.1038/ncb3064 [PubMed: 25402683]
159. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H (2007) Autocrine glutamate signaling promotes glioma cell invasion. *Cancer Res* 67 (19):9463–9471. doi:10.1158/0008-5472.CAN-07-2034 [PubMed: 17909056]
160. Xie Y, Song X, Sun X, Huang J, Zhong M, Lotze MT, Zeh HJR, Kang R, Tang D (2016) Identification of baicalein as a ferroptosis inhibitor by natural product library screening. *Biochem Biophys Res Commun* 473 (4):775–780. doi:10.1016/j.bbrc.2016.03.052 [PubMed: 27037021]
161. Probst L, Dachert J, Schenk B, Fulda S (2017) Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death. *Biochem Pharmacol* 140:41–52. doi:10.1016/j.bcp.2017.06.112 [PubMed: 28595877]
162. Shah R, Shchepinov MS, Pratt DA (2018) Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis. *ACS Cent Sci* 4 (3):387–396. doi:10.1021/acscentsci.7b00589 [PubMed: 29632885]
163. Johannesson T, Kristinsson J, Torsdottir G, Snaedal J (2012) [Ceruloplasmin (Cp) and iron in connection with Parkinson's disease (PD) and Alzheimer's disease (AD)]. *Laeknabladid* 98 (10):531–537 [PubMed: 23043066]
164. Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X, Wang H, Cao L, Tang D (2015) HSPB1 as a novel regulator of ferroptotic cancer cell death. *Oncogene* 34 (45):5617–5625. doi:10.1038/onc.2015.32 [PubMed: 25728673]
165. Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D (2016) Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. *Hepatology* 63 (1):173–184. doi:10.1002/hep.28251 [PubMed: 26403645]
166. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, Eaton ML, Keenan BT, Ernst J, McCabe C, Tang A, Raj T, Replogle J, Brodeur W, Gabriel S, Chai HS, Younkin C, Younkin SG, Zou F, Szyf M, Epstein CB, Schneider JA, Bernstein BE, Meissner A, Ertekin-Taner N, Chibnik LB, Kellis M, Mill J, Bennett DA (2014) Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. *Nat Neurosci* 17 (9):1156–1163. doi:10.1038/nn.3786 [PubMed: 25129075]




Figure 1. Induction and inhibition of ferroptosis.

Ferroptosis is induced by lethal lipid peroxidation in the central nervous system. Dysregulation of intracellular iron metabolism and/or glutathione peroxidation pathways leads to accumulation of lipid reactive oxygen species (ROS) and eventually causes cell death. Various inducers and inhibitors are shown. Arrows indicate promotion; blunt-ended lines indicate inhibition. ATF4, activating transcription factor 4; DFO, deferoxamine; FINO₂, 1, 2-dioxolane; FINs, ferroptosis-inducing agents; FtMt, mitochondrial ferritin; GPX4, glutathione peroxidase 4; GSH, glutathione; HMOX1, heme oxygenase-1; HpETE, HpETE-PE.

hydroperoxyeicosatetraenoic acid; KEAP1, Kelch-like ECH-associated protein 1; LOX, lipoxygenase; PE, phosphatidylethanolamine; PEBP1, phosphatidylethanolamine-binding protein 1; PUFA, polyunsaturated fatty acid; RSL3, Ras-selective lethal 3; TF, transferrin; TFR, transferrin receptor; VDAC2/3, voltage-dependent anion channel 2/3; WA, withaferin A.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. The role of ferroptosis in diverse brain diseases.

Various inducers and inhibitors in different brain diseases are shown. AD, Alzheimer's disease; CoQ₁₀, coenzyme Q₁₀; DFO, deferoxamine; DPI, diphenylene iodonium; Fer-1, ferrostatin-1; Flt3, FMS-like tyrosine kinase-3; PD, Parkinson's disease; PI3K α , phosphatidylinositol 3-kinase α ; PVL, periventricular leukomalacia; RSL3, Ras-selective lethal 3; WA, withaferin A.

Table 1.

Main inducers, inhibitors, and regulators in brain diseases relevant to ferroptosis

Target	Compound name/protein	Function	Brain diseases with relevance to ferroptosis
Inducers			
VDACs and system x_c^-	Erastin [1], erastin derivatives (PE [5], AE [133], IKE [133])	Reduces intracellular GSH content	Neuroblastoma [21]
System x_c^-	Sulfasalazine [134], sorafenib [135], lanperisone [136], glutamate [137]	Depletes GSH	PD [25], AD [72], HD [86], PVL [26], glioblastoma [107]
GPX4	RSL3 [1], (1S,3R)-RSL3 [5], DPI7 [5], DPI10 [5], DPI12 [5], DPI13 [5], DPI17 [5], DPI18 [5], DPI19 [5], ML162 [138], WA [118]	Directly inhibits GPX4, accumulation of lipid hydroperoxides	PD [139], AD [140], HD [88], ASL [141]
Lipid peroxidation	FINO ₂ [142], ART [143]	FINO ₂ indirectly inhibits GPX4 function and directly oxidizes iron, leading to accumulation of lipid hydroperoxides. ART interacts with	AD [144], PD [145], HD [146], ASL [147], Friedreich's ataxia [148]
Inhibitors		lysosomal iron and generates ROS.	
Iron	t-BHP [149], ferric ammonium citrate [149], WA [118]	Increases iron abundance	Neurodegenerative diseases [149], ischemic stroke [42], ICH [23], aging [105], PD [150], neuroblastoma [118]
GSH	DPI2 [5], cisplatin [151], Ace [152], BSO [5]	Depletes GSH	PD [153], HD [87], AD [154], ALS [128], Friedreich's ataxia [155]
Iron	DFO [1], Ciclopirox olamine [156], 2,2-bipyridyl [1], deferoxamine [66]		Ischemic stroke [42], ICH [71], PD [71]
Lipid peroxidation	Fer-1 [1], SRS11-92 [26], SRS16-86 [157], trolox [1], liproxstatin-1 [158], vitamin E [1], CoQ ₁₀ [1], U0126 [50], FIt3 [96]	Chelates iron	AD [144], PD [25], ICH [50], HD [26], PVL [26], ischemic stroke [42]
Cysteine	β -mercaptoethanol [1]	Increases cysteine uptake	Glioma [159]
Lipoxygenase	Zileuton [16], baicalein [160], NDGA [161], PD146176 [162],	Blocks lipoxygenase-induced lipid peroxidation	HD [11], PVL [11]
Protein synthesis	CDC [11], AA861 [162]	Suppresses ferroptosis	Ischemic stroke [42], AD [163], PD [163]
Regulators	Cp [42]	Essential regulators	PD [139], HD [11], PVL [11]
	GPX4 [5]	Cancer cell regulators	Glioma [111]
	P53 [6], HSPB1 [164], Rb [135], SLC7A11 [109], VDACS [12], Nrf2 [165], ATF4 [134]	Mitochondrial genes	AD [166]
	RPL13 [166], IREB2 [1], ATP5G3 [1], CS [1], TTC35 [1], ACSF2 [1]		

ACSF2, acyl-CoA synthetase family member 2; AD, Alzheimer's disease; AE, aldehyde erastin; ALS, amyotrophic lateral sclerosis; ART, artesunate; ATF4, activating transcription factor 4; CoQ10, coenzyme Q10; Cp, ceruloplasmin; CS, citrate synthase; DFO, deferoxamine; DPI, diphenylene iodonium; Fer-1, ferrostatin-1; FINO₂, 1, 2-dioxolane; FIt3, FMS-like tyrosine kinase-3; GPX4, glutathione peroxidase 4; GSH, glutathione; HD, Huntington's disease; HSPB1, heat shock protein β -1; ICH, intracerebral hemorrhage; IKE, imidazole ketone erastin; IREB2, iron response element binding protein 2;

NDGA, nordihydroguaiaretic acid; Nrf2, nuclear factor E2-related factor 2; PD Parkinson's disease; PE, phosphatidylethanolamines; PVL, periventricular leukomalacia; Rb, retinoblastoma; ROS, reactive oxygen species; RPL13, ribosomal protein L13; RSL3, Ras-selective lethal 3; t-BHP, tert-butylhydroperoxide; TTC35, tetraatricopeptide repeat domain 35; VDACs, voltage-dependent anion channels; WA, withaferin A.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript